These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
57 related articles for article (PubMed ID: 10788174)
1. A tailor-made vaccine. Scientists try a new strategy to combat cancer. Sobel R US News World Rep; 2000 Mar; 128(10):53. PubMed ID: 10788174 [No Abstract] [Full Text] [Related]
8. A convenient cancer vaccine therapy with in vivo transfer of interleukin 12 expression plasmid using gene gun technology after priming with irradiated carcinoma cells. Nishitani MA; Sakai T; Ishii K; Zhang M; Nakano Y; Nitta Y; Miyazaki J; Kanayama HO; Kagawa S; Himeno K Cancer Gene Ther; 2002 Feb; 9(2):156-63. PubMed ID: 11857033 [TBL] [Abstract][Full Text] [Related]
9. Reduced L-selectin (CD62LLow) expression identifies tumor-specific type 1 T cells from lymph nodes draining an autologous tumor cell vaccine. Meijer SL; Dols A; Hu HM; Chu Y; Romero P; Urba WJ; Fox BA Cell Immunol; 2004 Feb; 227(2):93-102. PubMed ID: 15135291 [TBL] [Abstract][Full Text] [Related]
10. A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease. Dessureault S; Noyes D; Lee D; Dunn M; Janssen W; Cantor A; Sotomayor E; Messina J; Antonia SJ Ann Surg Oncol; 2007 Feb; 14(2):869-84. PubMed ID: 17103257 [TBL] [Abstract][Full Text] [Related]
11. [Efficacy of autologous renal tumor cell lysate-loaded dendritic cell vaccine in combination with cytokine-induced killer cells on advanced renal cell carcinoma--a report of ten cases]. Wang H; Zhou FJ; Wang QJ; Qin ZK; Huang LX; Liu ZW; Han H; Li YQ; Chen SP; Xia JC Ai Zheng; 2006 May; 25(5):625-30. PubMed ID: 16687087 [TBL] [Abstract][Full Text] [Related]
12. Adjuvant autologous tumour cell-lysate vaccine versus no adjuvant treatment in patients with M0 renal cell carcinoma after radical nephrectomy: 3-year interim analysis of a German multicentre phase-III trial. Doehn Ch; Richter A; Lehmacher W; Jocham D Folia Biol (Praha); 2003; 49(2):69-73. PubMed ID: 12779015 [TBL] [Abstract][Full Text] [Related]
13. An effective tumor vaccine optimized for costimulation via bispecific and trispecific fusion proteins. Aigner M; Janke M; Lulei M; Beckhove P; Fournier P; Schirrmacher V Int J Oncol; 2008 Apr; 32(4):777-89. PubMed ID: 18360705 [TBL] [Abstract][Full Text] [Related]
16. Fusion hybrids of dendritic cells and autologous myeloid blasts as a potential cellular vaccine for acute myeloid leukaemia. Klammer M; Waterfall M; Samuel K; Turner ML; Roddie PH Br J Haematol; 2005 May; 129(3):340-9. PubMed ID: 15842657 [TBL] [Abstract][Full Text] [Related]
17. [Zeta chain level of T and NK cells in patients with renal-cell carcinoma and bladder cancer and its clinical significance]. Han Y; Li CL; Lu L; Zhou CX; Ma WB; Wang DM; Zhang SR Zhonghua Zhong Liu Za Zhi; 2004 Mar; 26(3):158-60. PubMed ID: 15196436 [TBL] [Abstract][Full Text] [Related]
18. Vaccine therapy in patients with renal cell carcinoma. Van Poppel H; Joniau S; Van Gool SW Eur Urol; 2009 Jun; 55(6):1333-42. PubMed ID: 19201522 [TBL] [Abstract][Full Text] [Related]
19. Retraction ends furore over cancer vaccine. Abbott A Nature; 2003 Sep; 425(6953):4. PubMed ID: 12955102 [No Abstract] [Full Text] [Related]
20. Allogeneic whole-cell vaccine: a phase I/II study in men with hormone-refractory prostate cancer. Eaton JD; Perry MJ; Nicholson S; Guckian M; Russell N; Whelan M; Kirby RS BJU Int; 2002 Jan; 89(1):19-26. PubMed ID: 11849155 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]